We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01514500
Recruitment Status : Completed
First Posted : January 23, 2012
Last Update Posted : December 24, 2020
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to placebo in healthy male subjects.

Condition or disease Intervention/treatment Phase
Growth Hormone Disorder Adult Growth Hormone Deficiency Growth Hormone Deficiency in Children Healthy Drug: somapacitan Drug: placebo (somapacitan) Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
Actual Study Start Date : January 16, 2012
Actual Primary Completion Date : March 18, 2013
Actual Study Completion Date : March 18, 2013

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Single dose (SD)
Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
 Drug: somapacitan
Administered s.c. (subcutaneously, under the skin)
Other Name: NNC0195-0092

Drug: placebo (somapacitan)
Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
Experimental: Multiple dose (MD)
Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
 Drug: somapacitan
Administered s.c. (subcutaneously, under the skin)
Other Name: NNC0195-0092

Drug: placebo (somapacitan)
Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of adverse events (Single Dose) [ Time Frame: From first administration of trial product and up until day 40 ]
  2. Incidence of adverse events (Multiple Dose) [ Time Frame: From first administration of trial product and up until day 49 ]

Secondary Outcome Measures :
  1. Area under the NNC0195-0092 (somapacitan) serum concentration-time curve [ Time Frame: From 0 to 168 hours ]
  2. Area under the NNC0195-0092 (somapacitan) serum concentration-time curve (SD part only) [ Time Frame: From 0-240 hours ]
  3. Area under the NNC0195-0092 (somapacitan) serum concentration-time curve (SD part only) [ Time Frame: up to day 40 ]
  4. Maximum serum concentration (Cmax) for NNC0195-0092 (somapacitan) [ Time Frame: up to day 40 ]
  5. Area under the IGF-I (insulin-like growth factor-I) serum concentration-time curve [ Time Frame: From 0-168 hours ]
  6. Area under the IGF-I (insulin-like growth factor-I) serum concentration-time curve (SD part only) [ Time Frame: From 0-240 hours ]
  7. Maximum serum concentration (Cmax) for IGF-I [ Time Frame: up to day 40 ]
  8. Area under the IGFBP-3 (insulin-like growth factor binding protein-3) serum concentration-time curve [ Time Frame: From 0-168 hours ]
  9. Area under the IGFBP-3 (insulin-like growth factor binding protein-3) serum concentration-time curve (SD part only) [ Time Frame: From 0-240 hours ]
  10. Maximum serum concentration (Cmax) for IGFBP-3 [ Time Frame: up to day 40 ]
  11. Number of injection site reactions [ Time Frame: From first administration of trial product and up until day 40 (SD part) ]
  12. Number of injection site reactions [ Time Frame: From first administration of trial product and up until day 49 (MD part) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy, non-smoking male subjects
  • BMI (body mass index) between 18.0 and 28.0 kg/m^2, both incl.
  • Body weight 50 to 100 kg, both incl.

Exclusion Criteria:

  • Strenuous exercise within 4 days prior to dosing
  • Receipt of any investigational medicinal product within 3 months prior to randomisation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514500


Locations
Layout table for location information
Germany
Novo Nordisk Investigational Site
Neuss, Germany, 41460
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Global Clinical Registry (GCR,1452) Novo Nordisk A/S
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01514500    
Other Study ID Numbers: NN8640-3915
U1111-1119-0539 ( Other Identifier: WHO )
2011-000146-38 ( EudraCT Number )
First Posted: January 23, 2012    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism, Pituitary
Endocrine System Diseases
Dwarfism
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
 Hypopituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases